Adriamycin, Vincristine and Prednisone in the Treatment of Malignant Tumors Resistant to Conventional Chemotherapy

  • H. J. Senn
  • W. F. Jungi
  • A. C. Mayr
  • G. A. Nagel
Conference paper

Abstract

Adriamycin (14-hydroxy-daunorubicine), a new cytotoxic antibiotic isolated from cultures of streptomyces peuceticus var. caesius, was introduced to clinical chemotherapy of human neoplasms in 1969 by Bonadonna and co-workers [1]. The drug seems to have significant antitumor activity in a much larger spectrum of malignant diseases than daunorubicine, especially in solid tumors [1-3]. It has mainly been used as a single agent. It was the aim of this study to explore antitumor effect and toxicity of the combination chemotherapy with adriamycin, vincristine and prednisone.

Keywords

Toxicity Depression Leukemia Sarcoma Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonadonna, G., Monfardini, S., De Lena, M., Fossati-Bellani, F.: Brit. med. J. 1969III, 503–506.Google Scholar
  2. 2.
    Bonadonna, G., Monfardini, S., Delena, M., Fossati-Bellani, F.: Cancer Res. 30, 2572–2582 (1970).PubMedGoogle Scholar
  3. 3.
    Obrecht, P., Westerhausen, M., Simon, A.: Dtsch. med. Wschr. 96, 369–376 (1971).PubMedCrossRefGoogle Scholar
  4. 4.
    Swiss Group for Clinical Cancer Research, protocol 23/72. Adriamycin was kindly supplied for this study by Deutsche Farmitalia GmbH, Freiburg i. Br./Germany.Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1972

Authors and Affiliations

  • H. J. Senn
    • 1
  • W. F. Jungi
    • 1
  • A. C. Mayr
    • 1
  • G. A. Nagel
    • 1
  1. 1.Oncology CenterBasel University ClinicsBaselSwitzerland

Personalised recommendations